The US is vulnerable to shedding some of the essential know-how races of the twenty first century: biotechnology. A 2025 report from a bipartisan, congressionally chartered fee warns that China is closing in on a win, and the US has solely a slim window to reply.
The report, launched by the Nationwide Safety Fee on Rising Biotechnology, gives dozens of suggestions, starting from growing federal funding and increasing home manufacturing to decreasing reliance on Chinese language suppliers and enhancing interagency coordination. However one problem receives too little consideration. If the US desires to compete, it should restore belief within the mental property rights that allow inventors to show daring concepts into revolutionary merchandise.
Patents make high-risk innovation financially viable. They permit startups to guard their discoveries, entice capital, and develop. With out dependable patent rights, promising analysis will get shelved — or picked up and superior overseas.
This isn’t theoretical. The US led previous waves of innovation — just like the explosion of biotech startups after the Bayh-Dole Act of 1980 and the Nineteenth-century surge of invention that introduced us the phone and car — exactly as a result of it backed inventors with clear, enforceable IP rights.
In biotech, the stakes are greater. The sphere is remodeling how we deal with illness, develop meals, and manufacture every part from chemical substances to superior supplies. And with synthetic intelligence accelerating discovery, the tempo is exponential. Because the Fee notes, instruments like AlphaFold from Google DeepMind can now mannequin lots of of hundreds of thousands of protein buildings in days, a activity that after took years.
China noticed this future coming. For greater than 20 years, it has handled biotechnology as a nationwide strategic precedence, pouring cash into analysis, constructing huge biomanufacturing capability, and buying overseas IP by way of each authorized and illicit means.
At present, Chinese language corporations produce most of the substances U.S. drugmakers depend on. In keeping with the Fee, almost 80% of American drugmakers rely on Chinese language contractors for a part of their provide chain.
In a disaster, that sort of reliance may go away Individuals with out entry to vital drugs. The Fee outlines a state of affairs by which Chinese language researchers develop a breakthrough most cancers remedy and withhold it throughout a disaster over Taiwan.
Provide chains collapse. Docs ration care. The White Home faces an inconceivable alternative: maintain the road on overseas coverage or safe entry to lifesaving drugs.
The state of affairs is fictional, however the menace is actual.
It doesn’t cease there. The report warns that if China stays on its present path, it may quickly management the organic knowledge, manufacturing platforms, and AI instruments driving the subsequent technology of commercial and protection applied sciences.
When innovation stays on U.S. soil, so do the roles, knowledge, and provide chains that defend our residents. If the applied sciences that outline the long run are as an alternative developed underneath adversarial regimes, the US dangers dependence on overseas powers not just for merchandise however for strategic capabilities. Falling behind wouldn’t simply price the US market share. It will endanger nationwide safety and world affect.
The Fee is correct to emphasise the necessity for a stronger home biotech sector. However efforts to attain that objective will fall brief except we repair the inspiration that permits innovation within the first place.
That basis, our IP system, is underneath critical pressure. Over the previous decade, courtroom selections have blurred the boundaries of what qualifies for patent safety — what’s “patent eligible” — particularly in medical diagnostics, artificial biology, and AI-enabled analysis.
And even when patents are granted, defending them has develop into more durable. A bit of-known administrative physique known as the Patent Trial and Enchantment Board (PTAB) lets huge companies repeatedly attempt to invalidate opponents’ patents, forcing startups into costly and drawn-out authorized battles.
On the similar time, a 2006 Supreme Court docket determination made it more durable for courts to problem authorized orders known as injunctions — which cease infringers from persevering with to make use of others’ innovations — even in circumstances of clear wrongdoing.
These tendencies have a chilling impact. Buyers hesitate to fund science except they’ll depend on the underlying IP rights. In biotech, the place it may price billions of {dollars} and greater than a decade to develop a single product, that hesitation can kill total pipelines of innovation.
The excellent news is that Congress has instruments to alter course. Three bipartisan proposals within the Home and Senate would assist. One invoice would restore readability to patent eligibility requirements. One other would reform PTAB procedures to curb duplicative challenges to patents. A 3rd would make it simpler for courts to block infringers by issuing injunctions.
Collectively, these reforms would scale back uncertainty, restore steadiness, and make the US a extra enticing place to innovate and make investments.
We nonetheless have important benefits: world-class analysis establishments, deep capital markets, and a free market that rewards daring concepts. However because the Fee warns, our lead is slipping — and time is brief. To remain forward within the race for biotech dominance, we have to repair the IP system that makes American innovation doable.
The opinions expressed in Fortune.com commentary items are solely the views of their authors and don’t essentially mirror the opinions and beliefs of Fortune.
This story was initially featured on Fortune.com
